Your browser doesn't support javascript.
loading
The Diagnostic and Treatment Challenges of Concomitant Mantle Cell Lymphoma and IgM Myeloma.
Gor, Dhairya; Mehta, Rohan; Greenberg, David; Angelova, Evgeniya.
Afiliación
  • Gor D; Internal Medicine Department, Jersey Shore Medical Center, Neptune, NJ, USA.
  • Mehta R; Hematology Oncology Department, Jersey Shore Medical Center, Neptune, NJ, USA.
  • Greenberg D; Hematology Oncology Department, Jersey Shore Medical Center, Neptune, NJ, USA.
  • Angelova E; Pathology Department, Jersey Shore Medical Center, Neptune, NJ, USA.
Eur J Case Rep Intern Med ; 9(7): 003463, 2022.
Article en En | MEDLINE | ID: mdl-36051172
ABSTRACT
It is rare for IgM multiple myeloma (MM) and mantle cell lymphoma (MCL) to coexist. Furthermore, it is challenging to demonstrate if there are two distinct types of neoplasia or if plasma cell differentiation of MCL is present. We discuss the case of a patient concomitantly diagnosed with MCL and IgM MM, and the subsequent diagnostic and management difficulties, and the positive treatment outcome. LEARNING POINTS Due to the rarity of simultaneous multiple myeloma (MM) and mantle cell lymphoma (MCL), it is challenging to investigate a possible association.This report will draw attention to the condition's rarity, diagnostic and treatment hurdles, and hopefully inspire future research into therapeutic alternatives.Several recent developments indicate a bright future for treating refractory malignancies such as MM and MCL, such as the advent of chimeric antigen receptor T-cell (CAR T-cell) therapy.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Eur J Case Rep Intern Med Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Eur J Case Rep Intern Med Año: 2022 Tipo del documento: Article